Business Wire

DNA and Sagemcom Launch the DNA TV-hubi, an Open Android TVTM hub

Jaa

DNA TV-hubi, launched last month by DNA, is an Android TV based device for TV and multimedia entertainment, designed and manufactured by Sagemcom, consisting in a 4K UHD set-top box for TV viewing and giving access to thousands of apps through Google Play TM app store.

This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170911005358/en/

The DNA TV-hubi enables to access all terrestrial channels as well as DNA’s cable channels. Thanks to an embedded dual tuner, users can watch a channel and record another one on an external 1TB hard disk drive. The product can receive HD and 4K UHD contents, and when connected to a 4K TV set, the subscriber watching 4K contents enjoys a crystal clear picture with four times the resolution of Full HD. Last but not least, the set-top box allows to receive the pay-TV channels through a broadband connection, so even when not within the coverage area of DNA’s cable or terrestrial networks.

The device, thanks to its embedded certified Android TV operating system, brings access to thousands of downloadable applications through Google Play, such as YouTubeTM – including for 4K contents – Katsomo, Yle Areena and Ruutu to enjoy the 3 major TV channels in Finland, and hundreds of games. Netflix is also supported and will be available this month. Support of Google CastTM enables screen sharing for contents.

The product is designed and manufactured by Sagemcom, and built around the 4K UHD BCM7252S SoC of Broadcom. Sagemcom also carried out the integration and the certification of Android TV operating system that manages all the applications available on the product, as well as the integration of Netflix and DNA TV application. The device embeds software-based encryption system for pay-TV channels, which allows receiving these contents without any TV cards. Sensitive assets from Android universe are also protected with a cardless DRM system.

“We are proud to introduce with DNA this new 4K Android TV set-top box in Finland, that brings the users an enriched entertainment experience thanks to full set of features and the available apps”, said Olivier Taravel, Deputy Chief Executive Officer of Sagemcom Broadband. “4K UHD set-top boxes are key products for the company, at the forefront of Ultra HD technology. Sagemcom relies on a strategic partnership with Broadcom to propose our customers a full range of always more powerful and innovative 4K STBs, including latest generation of Android TV devices.”

“The unique, ground-breaking set-top box - DNA TV-hubi - is for us, as the leading pay-TV operator in Finland, a great opportunity to offer our pay-TV services to all homes in our country with a single device, either through DNA’s cable, terrestrial or IPTV. Android TV’s Google Play store gives customers instant ability to enjoy hugely popular services such as Netflix and Youtube TM , as well as gaming and Google Cast TM . With 4K UHD we can be sure that DNA’s customers will always enjoy the best viewing experience in Finland,” says Ville Partanen, Director of Product Development at DNA.

About Sagemcom

A French high-tech group of international dimensions, Sagemcom operates on the broadband (digital home, set-top boxes, Internet routers, telephony and multimedia terminals), smart city (smart meter, smart grid, smart infra, smart sites and smart services), and Internet of Things markets.
With revenue of around 1.6 billion euros, Sagemcom employs 4000 people on five continents and ships every year more than 25 million terminals. Sagemcom aims to remain a world leader in communicating terminals with high added value.

www.sagemcom.com // www.facebook.com/SagemcomOfficial // https://twitter.com/Sagemcom

About DNA

DNA Plc is a Finnish telecommunications group providing high-quality voice, data and TV services for communication, entertainment and working. DNA is Finland's largest cable operator and the leading pay TV provider in both cable and terrestrial networks. For DNA, the key area for growth in corporate business is the new way of working, independent of time and place, facilitated by smart terminal devices, diverse communications services and rapid connections. In 2016, DNA recorded net sales of EUR 859 million and an operating profit of EUR 91 million. DNA has more than 3.8 million subscriptions in its fixed and mobile communications networks. The Group also includes DNA Store, Finland's largest retail chain selling mobile phones. DNA shares are listed on Nasdaq Helsinki Ltd. For further information, visit www.dna.fi or follow us on Twitter @DNA_fi, @DNA_Business and @DNA_Palvelu and Facebook.

Android TV, Google Play, YouTube and Google Cast are trademarks of Google, Inc.

DNA, DNA TV and DNA TV Hubi are registered trademarks of DNA Plc.

Contact information

Media:
DNA Corporate Communications
tel. +358 44 044 8000
communications@dna.fi
or
Sagemcom
Sylvaine COULEUR, tel. +33 6 99 37 63 48
presse@sagemcom.com

Tietoja julkaisijasta

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Tilaa tiedotteet sähköpostiisi

Haluatko tietää asioista jo ennen kuin ne uutisoidaan? Kun tilaat tiedotteemme, saat ne sähköpostiisi yhtä aikaa suomalaisen median kanssa. Tilauksen voit halutessasi perua milloin tahansa.

Lue lisää julkaisijalta Business Wire

ERYTECH Announces Filing of 2017 “Document de Référence” and 2017 Annual Report on Form 20-F24.4.2018 23:30Tiedote

Regulatory News: ERYTECH Pharma (Euronext Paris: ERYP – Nasdaq: ERYP), the clinical-stage biopharmaceutical company developing innovative therapies for severe forms of cancer and orphan diseases based on its proprietary ERYCAPS platform, encapsulating therapeutic drug substances inside red blood cells, today announced that it had filed its 2017 “Document de Référence” for the year ended December 31, 2017, including the management report and the annual financial report with the “Autorité des Marchés Financiers (AMF)” and its Annual Report on Form 20-F for the year ended December 31, 2017 with the U.S. Securities and Exchange Commission (SEC). These documents can be accessed on the Investors section of the Company’s corporate website (www.erytech.com). In addition, the “Document de Référence” is also available on the AMF’s website (http://www.amf-france.org) and the Annual Report on Form 20-F is also available on the SEC’s website (www.sec.gov). Printed copies of these documents are also

Rimini Street Launches New Solutions that Further Extend the Life and Value of Enterprise Software as a Foundation for Innovation24.4.2018 19:00Tiedote

Rimini Street, Inc . (Nasdaq: RMNI), a global provider of enterprise software products and services, and the leading third-party support provider for Oracle and SAP software products, today announced the first offerings in a family of solutions designed to provide improved competitive advantage to organizations with mature and valuable enterprise software investments that can be used as a foundation for innovation. Rimini Street’s new solutions can enable an organization to quickly and cost-effectively modernize their current enterprise software with the latest desired features and capabilities, future-proof their technical platforms against yet-unknown technology changes, and secure their systems against a constantly evolving threat environment. Rimini Street’s new solutions enable organizations to leverage their existing systems as a solid foundation for an innovative hybrid IT strategy. This press release features multimedia. View the full release here: https://www.businesswire.com/

Novaliq to Present Scientific and Clinical Research During the 2018 Association for Research in Vision and Ophthalmology Meeting in Honolulu, HI24.4.2018 18:53Tiedote

Novaliq GmbH, a specialty pharmaceutical company with a disruptive drug delivery platform that transforms poorly soluble drugs into effective therapeutics for ophthalmology, today announced that four scientific posters will be presented at the 2018 Association for Research in Vision and Ophthalmology (ARVO) Meeting in Honolulu, HI (April 29-May 3). The variety of data to be presented reflects Novaliq’s dedication to science and clinical research. With the collection of posters, Novaliq will share clinical and pre-clinical data on its EyeSol® drug delivery technology and provide insights into the mode of action of its NOV03/NovaTears® water-free therapy for the treatment of dry eye disease (DED). Furthermore, Novaliq will present its first pre-clinical efficacy data in glaucoma. Scientific posters supported by Novaliq will include: “Influence of perfluorohexyloctane containing eye drops on tear film thickness in patients with mild to moderate dry eye disease.” Authors: Garhöfer G., Schm

PPG Reports Sustainability Progress, New 2025 Goals24.4.2018 16:07Tiedote

PPG (NYSE:PPG) today released its 2017 Corporate Sustainability Report, which details the company’s continued progress in strengthening its sustainable operations in 2017 and the launch of new, aggressive sustainability goals it aims to achieve by 2025. The report is available at sustainability.ppg.com. “PPG’s sustainability efforts go beyond product innovations to extend to our customers’ operations and the communities in which we operate,” said Mark Cancilla, PPG vice president, environment, health and safety. “We are encouraged by our progress in 2017 and excited about our new goals, which are representative of the challenges and opportunities of our current business portfolio.” The company achieved the following progress in 2017: 32 percent of sales from products that provide customers with a sustainable advantage, an increase of 60 percent since 2012. This includes the unveiling of multiple products that provide a sustainable solution, such as Sigma Air Pure, a revolutionary bio-b

WeQ Launches to Transform Mobile Ad Tech with Human Intelligence and Inclusivity24.4.2018 16:00Tiedote

WeQ, a mobile ad tech brand providing user acquisition and engagement services at a global scale, announced today its official launch. WeQ is driven by a forward-thinking, socio-economic movement striving to shift from an exclusive ‘I’ culture to a collaborative ‘We’ culture. Setting its sights on becoming a trusted leader in the mobile ad tech industry, WeQ combines innovative data-driven technology with the collective human intelligence of its accomplished team of mobile ad tech experts to empower companies to reach their goals. WeQ comes out of the gate armed with a strategic investment, having secured more than $50 million USD in internal funds and debt capital to accelerate an ambitious global growth path. The ad tech brand plans to use the funds as it undertakes an aggressive M&A strategy. Over the next 12-24 months, WeQ plans to acquire cutting-edge technologies from innovative ventures to expand its technological footprint and services, attract international talent, and enter n

Bioiberica Approves Its Combined Drug for Osteoarthritis in Five More European Countries24.4.2018 15:17Tiedote

Bioiberica's combination of chondroitin sulphate and glucosamine hydrochloride, a slow action drug to treat osteoarthritis symptoms, was approved as an ethical drug in France, Austria, Hungary, Poland, and Finland through a mutual recognition process from Spain. ‘This approval confirms that Drug Agencies from different countries attest to the effectiveness and safety of the combination of pharmaceutical grade chondroitin sulphate and glucosamine hydrochloride. This drug has proven to reduce pain and improve mobility in people affected by knee osteoarthritis which, due to its safety profile, could also be used as an alternative by those patients with cardiovascular or gastrointestinal problems who should not be prescribed anti-inflammatory drugs chronically’, stated Dr Juan Gispert, Bioiberica's R&D director. The principle study that guarantees its effectiveness is the MOVES clinical trial, published in the Annals of the Rheumatic Diseases, which concludes that the combination of chondr

Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.

Tutustu uutishuoneeseemme